Applications: |
Immunodepletion/Immunocompetition |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
FNDC5 Blocking Peptide for STJ501505 is synthetically produced from the sequence and is suitable for use in western blot applications. |
Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Gene Symbol: |
Fndc5 |
Gene ID: |
384061 |
Uniprot ID: |
FNDC5_MOUSE |
Specificity: |
This blocking peptide is recommended for use in combination with FNDC5 antibody, STJ501505 |
Immunogen: |
Synthetic peptide corresponding to unique amino acid sequences on human FNDC5 protein. |
Tissue Specificity | In adult, it is highly expressed in skeletal muscle, heart and brain. |
Post Translational Modifications | The extracellular domain is cleaved and released from the cell membrane. N-Glycosylated. |
Function | Irisin: Mediates beneficial effects of muscular exercise. Induces browning of white adipose tissue by stimulating UCP1 expression, at least in part, via the nuclear receptor PPARA. |
Peptide Name | Fibronectin Type Iii Domain-Containing Protein 5Fibronectin Type Iii Repeat-Containing Protein 2Peroxisomal ProteinPep Cleaved Into - Irisin |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinPeroxisome MembraneSecretedImported In Peroxisomes Through The Pex5 Receptor PathwayIrisin: SecretedDetected In The Blood Of Individuals Subjected To Endurance Exercise |
Alternative Peptide Names | Fibronectin Type Iii Domain-Containing Protein 5 proteinFibronectin Type Iii Repeat-Containing Protein 2 proteinPeroxisomal Protein proteinPep Cleaved Into - Irisin proteinFndc5 proteinFrcp2 proteinPep protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance